Erratum: Prospects for Treatment of Latent HIV (Clinical Pharmacology and Therapeutics (2013) 93 (46-56) DOI: 10.1038/clpt.2012.202);Prospects for treatment of latent HIV

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 46-56

  Barton, K M ^a   Burch, B D ^a   Soriano Sarabia, N ^a   Margolis, D M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BRYOSTATIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DISULFIRAM; GIVINOSTAT; HEXAMETHYLENEBISACETAMIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PROGRAMMED DEATH 1 RECEPTOR; PROSTRATIN; PROTEIN KINASE C; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZINC FINGER NUCLEASE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HEALTH CARE COST; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VACCINATION; VIRAL CLEARANCE;

EID: 84871273863     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.19     Document Type: Erratum

References (75)

1. WHO, UNICEF, and UNAIDS. Progress Report 2011: Global HIV/AIDS Response (2011).
2. Colin, L. & Van Lint, C. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology 6, 111 (2009).
3. Van Lint, C., Emiliani, S., Ott, M. & Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996).
4. Keedy, K.S., Archin, N.M., Gates, A.T., Espeseth, A., Hazuda, D.J. & Margolis, D.M. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83, 4749-4756 (2009).
5. Krishnan, V. & Zeichner, S.L. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J. Virol. 78, 9458-9473 (2004).
6. Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: A proof-ofconcept study. Lancet 366, 549-555 (2005).
7. Archin, N.M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
8. Siliciano, J.D. et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195, 833-836 (2007).
9. Matalon, S., Rasmussen, T.A. & Dinarello, C.A. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17, 466-472 (2011).
10. Lewin, S.R. HIV latency and eradication: Clinical perspectives. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012
11. Wightman, F., Ellenberg, P., Churchill, M. & Lewin, S.R. HDAC inhibitors in HIV. Immunol. Cell Biol. 90, 47-54 (2012).
12. Vojinovic, J. et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63, 1452-1458 (2011).
13. Furlan, A. et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17, 353-362 (2011).
14. Leoni, F. et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99, 2995-3000 (2002).
15. Archin, N.M., Espeseth, A., Parker, D., Cheema, M., Hazuda, D. & Margolis, D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
16. Xing, S. et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85, 6060-6064 (2011).
17. Doyon, G., Zerbato, J., Mellors, J.W. & Sluis-Cremer, N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog (PTEN). AIDS (2012); e-pub ahead of print 27 June 2012
18. Spivak, A. et al. Safety and feasibility of using disulfiram to enhance HIV transcription among long-term ARV-treated adults: Preliminary results from a pilot study. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012
19. Da Fonseca, S. et al. Purging the HIV-1 reservoir through disruption of the PD-1 pathway. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February-2 March 2011
20. Castro, P. et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res. Hum. Retroviruses 25, 1249-1259 (2009).
21. Persaud, D. et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 25, 2227-2234 (2011).
22. Garcia, F., Leon, A., Gatell, J.M., Plana, M. & Gallart, T. Therapeutic vaccines against HIV infection. Hum. Vaccin. Immunother. 8, 569-581 (2012).
23. Osborn, L., Kunkel, S. & Nabel, G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. USA. 86, 2336-2340 (1989).
24. Williams, S.A. et al. Prostratin antagonizes HIV latency by activating NFkappaB. J. Biol. Chem. 279, 42008-42017 (2004).
25. Boto, W.M., Brown, L., Chrest, J. & Adler, W.H. Distinct modulatory effects of bryostatin 1 and staurosporine on the biosynthesis and expression of the HIV receptor protein (CD4) by T cells. Cell Regul. 2, 95-103 (1991).
26. Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS ONE 4, e6093 (2009).
27. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5, e11160 (2010).
28. Morgan, R.J. Jr et al. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study. Invest. New Drugs 30, 723-728 (2012).
29. Choudhary, S.K., Archin, N.M. & Margolis, D.M. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J. Infect. Dis. 197, 1162-1170 (2008).
30. Klichko, V., Archin, N., Kaur, R., Lehrman, G. & Margolis, D. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J. Virol. 80, 4570-4579 (2006).
31. Contreras, X., Barboric, M., Lenasi, T. & Peterlin, B.M. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 3, 1459-1469 (2007).
32. Andreeff, M. et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent. Blood 80, 2604-2609 (1992).
33. Fernandez, G. & Zeichner, S.L. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7, 266 (2010).
34. Friedman, J. et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85, 9078-9089 (2011).
35. Xing, S. et al. Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Antimicrob. Chemother. 67, 398-403 (2012).
36. Micheva-Viteva, S. et al. High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J. Biol. Chem. 286, 21083-21091 (2011).
37. Sarkar, I., Hauber, I., Hauber, J. & Buchholz, F. HIV-1 proviral DNA excision using an evolved recombinase. Science 316, 1912-1915 (2007).
38. Mariyanna, L. et al. Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS ONE 7, e31576 (2012).
39. Huelsmann, P.M. et al. A suicide gene approach using the human proapoptotic protein tBid inhibits HIV-1 replication. BMC Biotechnol. 11, 4 (2011).
40. Samson, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725 (1996).
41. Hutter, G., Neumann, M., Nowak, D., Klein, S., Kluter, H. & Hofmann, W.K. The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation. J. Inflamm. (Lond). 8, 29 (2011).
42. Anderson, J. & Akkina, R. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology 2, 53 (2005).
43. Ma, Q. et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA 95, 9448-9453 (1998).
44. Schuitemaker, H. et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66, 1354-1360 (1992).
45. Keele, B.F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552-7557 (2008).
46. Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S. & Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621-628 (1997).
47. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2, 1240-1243 (1996).
48. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
49. de Roda Husman, A.M. et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 127, 882-890 (1997).
50. Allers, K. et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791-2799 (2011).
51. Hutter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
52. Henrich, T. J. et al. Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation in two HIV-positive individuals. XIX International AIDS Conference, Washington, DC, 22-27 July 2012
53. Perez, E.E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816 (2008).
54. Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zincfinger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839-847 (2010).
55. June, C. et al. Introduction of acquired CCR5 deficiency with zinc finger nuclease-modified autologous CD4 T cells (SB-728-T) correlates with increases in CD4 count and effects on viral load in HIV-infected subjects. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012
56. Lalezari, J. et al. A single infusion of zinc finger nuclease CCR5 modified autologous CD4 T cells (SB-728-T) increases CD4 counts and leads to decrease in HIV proviral load in an aviremic HIV-infected subject. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012
57. Westby, M. et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4- using virus reservoir. J. Virol. 80, 4909-4920 (2006).
58. Nedellec, R., Coetzer, M., Lederman, M.M., Offord, R.E., Hartley, O. & Mosier, D.E. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS ONE 6, e22020 (2011).
59. Wilen, C.B. et al. Engineering HIV-resistant human CD4+ T cells with CXCR4- specific zinc-finger nucleases. PLoS Pathog. 7, e1002020 (2011).
60. Y uan, J. et al. Zinc-finger nuclease editing of human CXCR4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol. Ther. 20, 849-859 (2012).
61. DiGiusto, D.L. et al. RNA-based gene therapy for HIV with lentiviral vectormodified CD34(+) cells in patients undergoing transplantation for AIDSrelated lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).
62. Wherry, E.J. T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
63. Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105, 3879-3884 (2008).
64. Migueles, S.A. et al. Defective human immunodeficiency virus-specific CD8+T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83, 11876-11889 (2009).
65. Barber, D.L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
66. Day, C.L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
67. Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
68. Petrovas, C. et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 110, 928-936 (2007).
69. Finnefrock, A.C. et al. PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. J. Immunol. 182, 980-987 (2009).
70. Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210 (2009).
71. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
72. Rosenblatt, J. et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34, 409-418 (2011).
73. Dai, B., Xiao, L., Bryson, P.D., Fang, J. & Wang, P. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific t cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol. Ther. 20,1800-1809 (2012).
74. Jin, H.T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 107, 14733-14738 (2010).
75. Kassu, A. et al. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol. 185, 3007-3018 (2010).